Cevimeline
- Generic Name
- Cevimeline
- Brand Names
- Evoxac
- Drug Type
- Small Molecule
- Chemical Formula
- C10H17NOS
- CAS Number
- 107233-08-9
- Unique Ingredient Identifier
- K9V0CDQ56E
- Background
Cevimeline is a parasympathomimetic agent that act as an agonist at the muscarinic acetylcholine receptors M1 and M3. It is indicated by the Food and Drug Administration for the treatment of dry mouth associated with Sjögren's syndrome.
- Indication
用于治疗各型青光眼。FDA批准用于干燥综合征和放疗引起的口干症。
- Associated Conditions
- Dry Mouth
Evoxac Demonstrates Efficacy in Alleviating Dry Mouth Symptoms in Sjögren's Syndrome Patients
• A meta-analysis of three clinical trials indicates that Evoxac (cevimeline hydrochloride) significantly improves salivary flow in Sjögren's syndrome patients.
• The review suggests Evoxac is a promising therapeutic option, especially for individuals experiencing mild to moderate salivary gland damage.
• Optimal dosage of Evoxac appears to be 30 mg three times daily, balancing efficacy and minimizing digestive system-related adverse effects.
• Further research is needed to confirm Evoxac's role as a reliable treatment for xerostomia across diverse populations and disease severities.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath